头孢匹罗、头孢他啶和头孢噻肟对铜绿假单胞菌、肠球菌、表皮葡萄球菌以及甲氧西林敏感和耐药、耐受和非耐受金黄色葡萄球菌的体外抑制和杀菌活性比较
Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.
作者信息
Goldstein E J, Citron D M
出版信息
Antimicrob Agents Chemother. 1985 Jul;28(1):160-2. doi: 10.1128/AAC.28.1.160.
Abstract
With a macrotube dilution method, MICs and MBCs were determined for three aminothiazolyl cephalosporins, cefpirome (HR 810), ceftazidime, and cefotaxime, against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-resistant, -susceptible, and -tolerant strains of Staphylococcus aureus. Comparatively, cefpirome was the most active agent against all gram-positive cocci, including enterococci and methicillin-resistant S. aureus, and was as active as ceftazidime against P. aeruginosa. MBCs of cefpirome were within two dilutions of the MICs for 91% of P. aeruginosa and 90% of gram-positive cocci strains tested, except methicillin-resistant S. aureus, for which the MBCs were within three dilutions for 90% of strains.
摘要
采用大试管稀释法，测定了三种氨噻唑基头孢菌素（头孢匹罗（HR 810）、头孢他啶和头孢噻肟）对铜绿假单胞菌、肠球菌、表皮葡萄球菌以及耐甲氧西林、甲氧西林敏感和甲氧西林耐受的金黄色葡萄球菌菌株的最低抑菌浓度（MIC）和最低杀菌浓度（MBC）。相比之下，头孢匹罗是对所有革兰氏阳性球菌（包括肠球菌和耐甲氧西林金黄色葡萄球菌）活性最强的药物，并且对铜绿假单胞菌的活性与头孢他啶相当。除耐甲氧西林金黄色葡萄球菌外，头孢匹罗对91%的铜绿假单胞菌和90%的革兰氏阳性球菌菌株的MBC在MIC的两个稀释度范围内，对于耐甲氧西林金黄色葡萄球菌，90%的菌株其MBC在三个稀释度范围内。
相似文献
1
Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.头孢匹罗、头孢他啶和头孢噻肟对铜绿假单胞菌、肠球菌、表皮葡萄球菌以及甲氧西林敏感和耐药、耐受和非耐受金黄色葡萄球菌的体外抑制和杀菌活性比较
Antimicrob Agents Chemother. 1985 Jul;28(1):160-2. doi: 10.1128/AAC.28.1.160.
2
Population analysis in strains of Staphylococcus aureus and Staphylococcus epidermidis. II. Cefuroxime and cefotaxime.
Acta Pathol Microbiol Immunol Scand B. 1983 Dec;91(6):425-9. doi: 10.1111/j.1699-0463.1983.tb00071.x.
3
Inhibitory and bactericidal activity of cefpirome and cefotaxime against blood culture isolates.
Chemotherapy. 1990;36(1):24-8. doi: 10.1159/000238744.
4
In-vitro and in-vivo activity of cefpirome (HR 810) against methicillin-susceptible and -resistant Staphylococcus aureus and Streptococcus faecalis.
J Antimicrob Chemother. 1989 Mar;23(3):373-81. doi: 10.1093/jac/23.3.373.
5
In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.新型胃肠外广谱头孢菌素FK037的体外抗菌活性
J Antibiot (Tokyo). 1993 Jan;46(1):71-87. doi: 10.7164/antibiotics.46.71.
6
Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.第三代头孢菌素：对常规临床分离株的抗菌活性比较
N Z Med J. 1982 Jun 23;95(710):414-6.
7
8
Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus.头孢匹罗与β-内酰胺酶抑制剂联合的活性以及对耐甲氧西林金黄色葡萄球菌青霉素结合蛋白的亲和力。
Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):364-71. doi: 10.1007/BF01962080.
9
The in-vitro activity of ceftazidime against clinically important pathogens.头孢他啶对临床重要病原菌的体外活性。
J Antimicrob Chemother. 1981 Sep;8 Suppl B:33-41. doi: 10.1093/jac/8.suppl_b.33.
10
In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.用改良琼脂稀释法检测头孢他啶、头孢噻肟和哌拉西林对多重耐药革兰氏阴性菌的体外活性。
Eur J Clin Microbiol. 1982 Jun;1(3):166-70. doi: 10.1007/BF02019618.
引用本文的文献
1
Population pharmacokinetics and dose optimization of ceftazidime in critically ill children.危重症儿童头孢他啶的群体药代动力学及剂量优化
Front Pharmacol. 2024 Nov 27;15:1470350. doi: 10.3389/fphar.2024.1470350. eCollection 2024.
2
Drug treatment of pneumonia in the elderly: efficacy and costs.老年人肺炎的药物治疗：疗效与成本
Pharmacoeconomics. 1993 Apr;3(4):268-75. doi: 10.2165/00019053-199303040-00003.
3
Nursing home-acquired pneumonia. Treatment options.养老院获得性肺炎。治疗选择。
Drugs Aging. 1996 May;8(5):338-48. doi: 10.2165/00002512-199608050-00003.
4
Cefpirome clinical pharmacokinetics.头孢匹罗的临床药代动力学。
Clin Pharmacokinet. 1993 Oct;25(4):263-73. doi: 10.2165/00003088-199325040-00002.
5
Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s.20世纪80年代肠球菌的易感性及肠球菌感染的流行病学。
Epidemiol Infect. 1989 Dec;103(3):403-13. doi: 10.1017/s0950268800030806.
6
Evaluation of two methods for overcoming the antibiotic carry-over effect.两种克服抗生素残留效应方法的评估
Eur J Clin Microbiol Infect Dis. 1991 Jan;10(1):34-8. doi: 10.1007/BF01967095.
7
Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus.头孢匹罗与β-内酰胺酶抑制剂联合的活性以及对耐甲氧西林金黄色葡萄球菌青霉素结合蛋白的亲和力。
Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):364-71. doi: 10.1007/BF01962080.
本文引用的文献
1
Treatment of infections due to methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌所致感染的治疗
Ann Intern Med. 1982 Sep;97(3):376-8. doi: 10.7326/0003-4819-97-3-376.
2
The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit.美国医院中耐甲氧西林金黄色葡萄球菌感染的出现。住院医生与患者转移循环的可能作用。
Ann Intern Med. 1982 Sep;97(3):297-308. doi: 10.7326/0003-4819-97-3-297.
3
The clinical significance of tolerance of Staphylococcus aureus.金黄色葡萄球菌耐受性的临床意义。
Ann Intern Med. 1980 Dec;93(6):924-6. doi: 10.7326/0003-4819-93-6-924.
4
In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.新型广谱氨噻唑基α-甲氧基氨基头孢菌素HR810的体外评价
Antimicrob Agents Chemother. 1984 Jun;25(6):710-8. doi: 10.1128/AAC.25.6.710.
5
In vitro activity of HR 810, a new cephalosporin.新型头孢菌素HR 810的体外活性
Antimicrob Agents Chemother. 1984 Aug;26(2):277-9. doi: 10.1128/AAC.26.2.277.
6
Resistance of methicillin-resistant staphylococcus aureus to third-generation cephalosporins.
J Infect Dis. 1983 Mar;147(3):591. doi: 10.1093/infdis/147.3.591.
7
Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.临床微生物实验室中第四代头孢菌素HR810的纸片扩散法检测、质量控制指南及抗菌谱
J Clin Microbiol. 1984 Sep;20(3):409-12. doi: 10.1128/jcm.20.3.409-412.1984.
8
Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients.
J Antimicrob Chemother. 1983 Jul;12 Suppl A:81-8. doi: 10.1093/jac/12.suppl_a.81.
9
Ceftazidime: aspects of efficacy and tolerance.头孢他啶：疗效与耐受性方面
J Antimicrob Chemother. 1983 Jul;12 Suppl A:399-403. doi: 10.1093/jac/12.suppl_a.399.
10
Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections.头孢他啶单药治疗严重铜绿假单胞菌感染。
J Antimicrob Chemother. 1983 Jul;12 Suppl A:207-11. doi: 10.1093/jac/12.suppl_a.207.
Zotero 插件